Resveratrol prevents ovariectomy-induced bone quality deterioration by improving the microarchitectural and biophysicochemical properties of bone.
Bone biology
Osteoporosis
Ovariectomy
Raman spectroscopy
Resveratrol
Journal
Journal of bone and mineral metabolism
ISSN: 1435-5604
Titre abrégé: J Bone Miner Metab
Pays: Japan
ID NLM: 9436705
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
10
11
2022
accepted:
01
03
2023
medline:
17
7
2023
pubmed:
9
4
2023
entrez:
8
4
2023
Statut:
ppublish
Résumé
Osteoporosis is a major health problem that is very common worldwide and is characterized by both low bone density and deterioration in bone quality. New treatment options without side effects have become an active area of research in recent years. This study was designed to investigate the preventive effects of resveratrol on bone quality deterioration caused by ovariectomy. Sixty rats were randomly divided into five groups (12 animals per group): Control, Sham-operated (SHAM), ovariectomized (OVX), OVX + Resveratrol-40 mg/kg/day (OVX + Res40), OVX + Resveratrol-80 mg/kg/day (OVX + Res80). Resveratrol was administered by oral gavage (40 and 80 mg/kg/day) for ten weeks. Micro-CT measurements, biomechanical testing, Raman spectroscopy analysis, and RT-PCR analysis were performed. ALP, OCN, TAS, and TOS levels were also measured from blood serum. Bone strength, bone volume/total volume, trabecular volume, and trabecular thickness were higher in the OVX + RES-80 group than in the OVX group. Resveratrol increased osteogenic differentiation, as the expression of osteogenic markers ALP, Col1A1, Runx2, OPG, OCN increased in both OVX + RES-80 and OVX + RES-40 groups compared to the OVX group. 80 mg/kg/day resveratrol administration decreased the levels of ALP, OCN and TOS in ovariectomized rats. Raman spectroscopy findings showed a preventive effect of resveratrol administration against ovariectomy-induced deterioration in biophysiochemical properties of bone tissue. This study revealed that administration of different doses of 80 mg/kg/day and 40 mg/kg/day of resveratrol had protective effects on bone quality deterioration caused by ovariectomy.
Identifiants
pubmed: 37031330
doi: 10.1007/s00774-023-01416-z
pii: 10.1007/s00774-023-01416-z
doi:
Substances chimiques
Resveratrol
Q369O8926L
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
443-456Subventions
Organisme : Pamukkale Üniversitesi
ID : 2021SABE007.
Informations de copyright
© 2023. The Japanese Society Bone and Mineral Research.
Références
Tou JC (2015) Resveratrol supplementation affects bone acquisition and osteoporosis: Pre-clinical evidence toward translational diet therapy. Biochim Biophys Acta 1852:1186–1194. https://doi.org/10.1016/j.bbadis.2014.10.003
doi: 10.1016/j.bbadis.2014.10.003
pubmed: 25315301
Gullberg B, Johnell O, Kanis JA (1997) World-wide projections for hip fracture. Osteoporos Int 7:407–413. https://doi.org/10.1007/pl00004148
doi: 10.1007/pl00004148
pubmed: 9425497
Zeng Q, Li N, Wang Q, Feng J, Sun D, Zhang Q, Huang J, Wen Q, Hu R, Wang L, Ma Y, Fu X, Dong S, Cheng X (2019) The prevalence of osteoporosis in china, a nationwide, multicenter DXA Survey. J Bone Miner Res 34:1789–1797. https://doi.org/10.1002/jbmr.3757
doi: 10.1002/jbmr.3757
pubmed: 31067339
Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 22:465–475. https://doi.org/10.1359/jbmr.061113
doi: 10.1359/jbmr.061113
pubmed: 17144789
Holroyd C, Cooper C, Dennison E (2008) Epidemiology of osteoporosis. Best Pract Res Clin Endocrinol Metab 22:671–685. https://doi.org/10.1016/j.beem.2008.06.001
doi: 10.1016/j.beem.2008.06.001
pubmed: 19028351
Beral V, Reeves G, Bull D, Green J (2011) Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst 103:296–305. https://doi.org/10.1093/jnci/djq527
doi: 10.1093/jnci/djq527
pubmed: 21278356
pmcid: 3039726
Chlebowski RT, Anderson G, Manson JE, Pettinger M, Yasmeen S, Lane D, Langer RD, Hubbell FA, McTiernan A, Hendrix S, Schenken R, Stefanick ML (2010) Estrogen alone in postmenopausal women and breast cancer detection by means of mammography and breast biopsy. J Clin Oncol 28:2690–2697. https://doi.org/10.1200/JCO.2009.24.8799
doi: 10.1200/JCO.2009.24.8799
pubmed: 20439627
pmcid: 2881849
Zhao M, Liu J, Zhang X, Peng L, Li C, Peng S (2009) 3D QSAR of novel estrogen-RGD peptide conjugates: getting insight into structural dependence of anti-osteoporosis activity and side effect of estrogen in ERT. Bioorg Med Chem 17:3680–3689. https://doi.org/10.1016/j.bmc.2009.03.057
doi: 10.1016/j.bmc.2009.03.057
pubmed: 19386502
Smoliga JM, Baur JA, Hausenblas HA (2011) Resveratrol and health–a comprehensive review of human clinical trials. Mol Nutr Food Res 55:1129–1141. https://doi.org/10.1002/mnfr.201100143
doi: 10.1002/mnfr.201100143
pubmed: 21688389
Novelle MG, Wahl D, Dieguez C, Bernier M, de Cabo R (2015) Resveratrol supplementation: Where are we now and where should we go? Ageing Res Rev 21:1–15. https://doi.org/10.1016/j.arr.2015.01.002
doi: 10.1016/j.arr.2015.01.002
pubmed: 25625901
pmcid: 5835393
Feng J, Liu S, Ma S, Zhao J, Zhang W, Qi W, Cao P, Wang Z, Lei W (2014) Protective effects of resveratrol on postmenopausal osteoporosis: regulation of SIRT1-NF-kappaB signaling pathway. Acta Biochim Biophys Sin (Shanghai) 46:1024–1033. https://doi.org/10.1093/abbs/gmu103
doi: 10.1093/abbs/gmu103
pubmed: 25377437
Zhao M, Ko SY, Garrett IR, Mundy GR, Gutierrez GE, Edwards JR (2018) The polyphenol resveratrol promotes skeletal growth in mice through a sirtuin 1-bone morphogenic protein 2 longevity axis. Br J Pharmacol 175:4183–4192. https://doi.org/10.1111/bph.14477
doi: 10.1111/bph.14477
pubmed: 30125963
pmcid: 6177622
Yu T, Wang Z, You X, Zhou H, He W, Li B, Xia J, Zhu H, Zhao Y, Yu G, Xiong Y, Yang Y (2020) Resveratrol promotes osteogenesis and alleviates osteoporosis by inhibiting p53. Aging (Albany NY) 12:10359–10369. https://doi.org/10.18632/aging.103262
doi: 10.18632/aging.103262
pubmed: 32459661
Shakibaei M, Buhrmann C, Mobasheri A (2011) Resveratrol-mediated SIRT-1 interactions with p300 modulate receptor activator of NF-kappaB ligand (RANKL) activation of NF-kappaB signaling and inhibit osteoclastogenesis in bone-derived cells. J Biol Chem 286:11492–11505. https://doi.org/10.1074/jbc.M110.198713
doi: 10.1074/jbc.M110.198713
pubmed: 21239502
pmcid: 3064204
Feng YL, Jiang XT, Ma FF, Han J, Tang XL (2018) Resveratrol prevents osteoporosis by upregulating FoxO1 transcriptional activity. Int J Mol Med 41:202–212. https://doi.org/10.3892/ijmm.2017.3208
doi: 10.3892/ijmm.2017.3208
pubmed: 29115382
Bhattarai G, Poudel SB, Kook SH, Lee JC (2016) Resveratrol prevents alveolar bone loss in an experimental rat model of periodontitis. Acta Biomater 29:398–408. https://doi.org/10.1016/j.actbio.2015.10.031
doi: 10.1016/j.actbio.2015.10.031
pubmed: 26497626
Omnia Ameen RIYaYMN (2020) Activation of FoxO1/SIRT1/RANKL/OPG pathway may underlie the therapeutic effects of resveratrol on aging-dependent male osteoporosis. BMC musculoskel disord. 21:389
Lin Q, Huang YM, Xiao BX, Ren GF (2005) Effects of resveratrol on bone mineral density in ovarectomized rats. Int J Biomed Sci 1:76–81
pubmed: 23674958
pmcid: 3614578
Wang X, Chen L, Peng W (2017) Protective effects of resveratrol on osteoporosis via activation of the SIRT1-NF-kappaB signaling pathway in rats. Exp Ther Med 14:5032–5038. https://doi.org/10.3892/etm.2017.5147
doi: 10.3892/etm.2017.5147
pubmed: 29201210
pmcid: 5704326
Wang W, Zhang LM, Guo C, Han JF (2020) Resveratrol promotes osteoblastic differentiation in a rat model of postmenopausal osteoporosis by regulating autophagy. Nutr Metab (Lond) 17:29. https://doi.org/10.1186/s12986-020-00449-9
doi: 10.1186/s12986-020-00449-9
pubmed: 32322287
Zhao H, Li X, Li N, Liu T, Liu J, Li Z, Xiao H, Li J (2014) Long-term resveratrol treatment prevents ovariectomy-induced osteopenia in rats without hyperplastic effects on the uterus. Br J Nutr 111:836–846. https://doi.org/10.1017/S0007114513003115
doi: 10.1017/S0007114513003115
pubmed: 24073920
Jiang Y, Luo W, Wang B, Wang X, Gong P, Xiong Y (2020) Resveratrol promotes osteogenesis via activating SIRT1/FoxO1 pathway in osteoporosis mice. Life Sci 246:117422. https://doi.org/10.1016/j.lfs.2020.117422
doi: 10.1016/j.lfs.2020.117422
pubmed: 32057903
Khera A, Kanta P, Kalra J, Dumir D (2019) Resveratrol restores the level of key inflammatory cytokines and RANKL/OPG ratio in the femur of rat osteoporosis model. J Women Aging 31:540–552. https://doi.org/10.1080/08952841.2018.1522126
doi: 10.1080/08952841.2018.1522126
pubmed: 30239309
Zhao L, Wang Y, Wang Z, Xu Z, Zhang Q, Yin M (2015) Effects of dietary resveratrol on excess-iron-induced bone loss via antioxidative character. J Nutr Biochem 26:1174–1182. https://doi.org/10.1016/j.jnutbio.2015.05.009
doi: 10.1016/j.jnutbio.2015.05.009
pubmed: 26239832
Durbin SM, Jackson JR, Ryan MJ, Gigliotti JC, Alway SE, Tou JC (2014) Resveratrol supplementation preserves long bone mass, microstructure, and strength in hindlimb-suspended old male rats. J Bone Miner Metab 32:38–47. https://doi.org/10.1007/s00774-013-0469-2
doi: 10.1007/s00774-013-0469-2
pubmed: 23686002
Karimian E, Tamm C, Chagin AS, Samuelsson K, Kjartansdottir KR, Ohlsson C, Savendahl L (2013) Resveratrol treatment delays growth plate fusion and improves bone growth in female rabbits. PLoS ONE 8:e67859. https://doi.org/10.1371/journal.pone.0067859
doi: 10.1371/journal.pone.0067859
pubmed: 23840780
pmcid: 3695926
Nair AB, Jacob S (2016) A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm 7:27–31. https://doi.org/10.4103/0976-0105.177703
doi: 10.4103/0976-0105.177703
pubmed: 27057123
pmcid: 4804402
Erel O (2005) A new automated colorimetric method for measuring total oxidant status. Clin Biochem 38:1103–1111. https://doi.org/10.1016/j.clinbiochem.2005.08.008
doi: 10.1016/j.clinbiochem.2005.08.008
pubmed: 16214125
Unal M, Ahmed R, Mahadevan-Jansen A, Nyman JS (2021) Compositional assessment of bone by Raman spectroscopy. Analyst 146:7464–7490. https://doi.org/10.1039/d1an01560e
doi: 10.1039/d1an01560e
pubmed: 34786574
pmcid: 8802336
Unal M, Uppuganti S, Timur S, Mahadevan-Jansen A, Akkus O, Nyman JS (2019) Assessing matrix quality by Raman spectroscopy helps predict fracture toughness of human cortical bone. Sci Rep 9:7195. https://doi.org/10.1038/s41598-019-43542-7
doi: 10.1038/s41598-019-43542-7
pubmed: 31076574
pmcid: 6510799
Donmez BO, Ozdemir S, Sarikanat M, Yaras N, Koc P, Demir N, Karayalcin B, Oguz N (2012) Effect of angiotensin II type 1 receptor blocker on osteoporotic rat femurs. Pharmacol Rep 64:878–888. https://doi.org/10.1016/s1734-1140(12)70882-4
doi: 10.1016/s1734-1140(12)70882-4
pubmed: 23087139
Turner CH (2002) Biomechanics of bone: determinants of skeletal fragility and bone quality. Osteoporos Int 13:97–104. https://doi.org/10.1007/s001980200000
doi: 10.1007/s001980200000
pubmed: 11905527
Donmez BO, Ozturk N, Sarikanat M, Oguz N, Sari R, Ozdemir S (2014) Sodium tungstate alleviates biomechanical properties of diabetic rat femur via modulation of oxidative stress. Gen Physiol Biophys 33:443–452. https://doi.org/10.4149/gpb_2014020
doi: 10.4149/gpb_2014020
pubmed: 25032510
Lee AM, Shandala T, Nguyen L, Muhlhausler BS, Chen KM, Howe PR, Xian CJ (2014) Effects of resveratrol supplementation on bone growth in young rats and microarchitecture and remodeling in ageing rats. Nutrients 6:5871–5887. https://doi.org/10.3390/nu6125871
doi: 10.3390/nu6125871
pubmed: 25521206
pmcid: 4277004
Li Y, Tseng WJ, de Bakker CMJ, Zhao H, Chung R, Liu XS (2021) Peak trabecular bone microstructure predicts rate of estrogen-deficiency-induced bone loss in rats. Bone 145:115862. https://doi.org/10.1016/j.bone.2021.115862
doi: 10.1016/j.bone.2021.115862
pubmed: 33493654
pmcid: 7920939
Mandair GS, Morris MD (2015) Contributions of Raman spectroscopy to the understanding of bone strength. Bonekey Rep 4:620. https://doi.org/10.1038/bonekey.2014.115
doi: 10.1038/bonekey.2014.115
pubmed: 25628882
pmcid: 4296861
Paschalis EP, Gamsjaeger S, Klaushofer K (2017) Vibrational spectroscopic techniques to assess bone quality. Osteoporos Int 28:2275–2291. https://doi.org/10.1007/s00198-017-4019-y
doi: 10.1007/s00198-017-4019-y
pubmed: 28378291
Unal M (2020) Letter to the Editor. Connect Tissue Res 61:420–422. https://doi.org/10.1080/03008207.2019.1666113
doi: 10.1080/03008207.2019.1666113
pubmed: 31913709
Unal M, Uppuganti S, Leverant CJ, Creecy A, Granke M, Voziyan P, Nyman JS (2018) Assessing glycation-mediated changes in human cortical bone with Raman spectroscopy. J Biophotonics. 11:201700352. https://doi.org/10.1002/jbio.201700352
doi: 10.1002/jbio.201700352
Unal M, Jung H, Akkus O (2016) Novel Raman Spectroscopic Biomarkers Indicate That Postyield Damage Denatures Bone’s Collagen. J Bone Miner Res 31:1015–1025. https://doi.org/10.1002/jbmr.2768
doi: 10.1002/jbmr.2768
pubmed: 26678707
Paschalis EP, Shane E, Lyritis G, Skarantavos G, Mendelsohn R, Boskey AL (2004) Bone fragility and collagen cross-links. J Bone Miner Res 19:2000–2004. https://doi.org/10.1359/JBMR.040820
doi: 10.1359/JBMR.040820
pubmed: 15537443
Wang X, Xu H, Huang Y, Gu S, Jiang JX (2016) Coupling Effect of Water and Proteoglycans on the In Situ Toughness of Bone. J Bone Miner Res 31:1026–1029. https://doi.org/10.1002/jbmr.2774
doi: 10.1002/jbmr.2774
pubmed: 26709950
Unal M, Akkus O (2015) Raman spectral classification of mineral- and collagen-bound water’s associations to elastic and post-yield mechanical properties of cortical bone. Bone 81:315–326. https://doi.org/10.1016/j.bone.2015.07.024
doi: 10.1016/j.bone.2015.07.024
pubmed: 26211992
pmcid: 4640992
Kawane T, Komori H, Liu W, Moriishi T, Miyazaki T, Mori M, Matsuo Y, Takada Y, Izumi S, Jiang Q, Nishimura R, Kawai Y, Komori T (2014) Dlx5 and mef2 regulate a novel runx2 enhancer for osteoblast-specific expression. J Bone Miner Res 29:1960–1969. https://doi.org/10.1002/jbmr.2240
doi: 10.1002/jbmr.2240
pubmed: 24692107
Lin GL, Hankenson KD (2011) Integration of BMP, Wnt, and notch signaling pathways in osteoblast differentiation. J Cell Biochem 112:3491–3501. https://doi.org/10.1002/jcb.23287
doi: 10.1002/jcb.23287
pubmed: 21793042
pmcid: 3202082
Liu Q, Zhang X, Jiao Y, Liu X, Wang Y, Li SL, Zhang W, Chen FM, Ding Y, Jiang C, Jin Z (2018) In vitro cell behaviors of bone mesenchymal stem cells derived from normal and postmenopausal osteoporotic rats. Int J Mol Med 41:669–678. https://doi.org/10.3892/ijmm.2017.3280
doi: 10.3892/ijmm.2017.3280
pubmed: 29207050
Gao Y, Patil S, Jia J (2021) The development of molecular biology of osteoporosis. Int J Mol Sci. https://doi.org/10.3390/ijms22158182
doi: 10.3390/ijms22158182
pubmed: 35008837
pmcid: 8745427
Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337–342. https://doi.org/10.1038/nature01658
doi: 10.1038/nature01658
pubmed: 12748652
Walsh MC, Choi Y (2014) Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond. Front Immunol 5:511. https://doi.org/10.3389/fimmu.2014.00511
doi: 10.3389/fimmu.2014.00511
pubmed: 25368616
pmcid: 4202272
Minamizaki T, Sakurai K, Hayashi I, Toshishige M, Yoshioka H, Kozai K, Yoshiko Y (2020) Active sites of human MEPE-ASARM regulating bone matrix mineralization. Mol Cell Endocrinol. 517:110931. https://doi.org/10.1016/j.mce.2020.110931
doi: 10.1016/j.mce.2020.110931
pubmed: 32712387
Minamizaki T, Yoshiko Y (2015) The bioactive acidic serine- and aspartate-rich motif peptide. Curr Protein Pept Sci 16:196–202. https://doi.org/10.2174/1389203716666150206122839
doi: 10.2174/1389203716666150206122839
pubmed: 25693768
Gowen LC, Petersen DN, Mansolf AL, Qi H, Stock JL, Tkalcevic GT, Simmons HA, Crawford DT, Chidsey-Frink KL, Ke HZ, McNeish JD, Brown TA (2003) Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass. J Biol Chem 278:1998–2007. https://doi.org/10.1074/jbc.M203250200
doi: 10.1074/jbc.M203250200
pubmed: 12421822
David V, Martin A, Hedge AM, Rowe PS (2009) Matrix extracellular phosphoglycoprotein (MEPE) is a new bone renal hormone and vascularization modulator. Endocrinology 150:4012–4023. https://doi.org/10.1210/en.2009-0216
doi: 10.1210/en.2009-0216
pubmed: 19520780
pmcid: 2819738
Guo D, Keightley A, Guthrie J, Veno PA, Harris SE, Bonewald LF (2010) Identification of osteocyte-selective proteins. Proteomics 10:3688–3698. https://doi.org/10.1002/pmic.201000306
doi: 10.1002/pmic.201000306
pubmed: 20845334
pmcid: 3517134